罗氟司特全网公布的2025年最新价格

Roflumilast is a drug used to treat chronic obstructive pulmonary disease (COPD). This article will give a detailed introduction to the latest price of roflumilast in 2025, global launch status, and drug preparation. By knowing this information, patients can better plan how to obtain and use this medication.

The latest price of roflumilast in 2025 published on the entire website

The price varies according to different regions and specifications. The following is the reference price of roflumilast in different regions in 2025.

Price of the German version of AstraZeneca in the UK

Roflumilast produced by AstraZeneca in the UK is exported to the German version in a specification of 500μg*30 tablets. The reference price in 2025 is approximately US$240 per box. The specification is 500μg*90 tablets, and the reference price is about US$400 per box. These prices may vary by pharmacy and purchase channel.

The price of the Hong Kong version of AstraZeneca in the UK

Roflumilast produced by AstraZeneca in the UK is exported to the Hong Kong version in a specification of 500μg*30 tablets. The reference price in 2025 is about US$140 per box. Prices in Hong Kong are relatively low and may be more suitable for patients with limited budgets.

Knowing the price of roflumilast can help patients make more informed decisions when choosing a treatment option. Price differences in different regions also provide patients with more choices.

Global marketing status of roflumilast

Roflumilast has been approved for marketing in many countries and regions around the world, but it is not yet available in some regions. The following is the marketing status of roflumilast in different regions.

U.S. market

Roflumilast was approved by the FDA in the United States in 2011 for the treatment of COPD. Its launch in the U.S. market provides patients with a new treatment option.

European market

Roflumilast has been approved in many European countries, including Germany, the United Kingdom and France. The drug's efficacy and safety are demonstrated by its broad acceptance on the European market.

Asian market

Roflumilast has also been launched in many Asian countries and regions, including Hong Kong, Japan and South Korea. The launch in the Asian market further expands the drug's global reach.

The global marketing status of roflumilast reflects its important position in the treatment of COPD. As more countries and regions recognize the drug, patients will have easier access to this effective treatment.

Preparation for roflumilast administration

The preparation for roflumilast administration needs to be determined according to the patient's specific situation and the doctor's advice. The following is some basic information about the preparation for roflumilast administration.

Physician consultation

Before starting to use roflumilast, patients should consult their doctor to understand the indications, contraindications and possible side effects of the drug. The doctor will decide whether this drug is suitable for use based on the patient's specific situation.

Liver function tests

Roflumilast may affect liver function, so patients should have liver function tests before starting the drug. Your doctor will use the test results to decide whether you need to adjust the dose or choose another treatment option.

Drug Storage

Roflumilast should be stored at room temperature and avoid high temperature and humid environments. Medications should be stored in a dry, cool place away from direct sunlight, and the packaging should be sealed after each use.

Patients should strictly follow the doctor's instructions and avoid adjusting the dosage or using uncertified drugs.